Account Bag 0

PRODUCT PROFILE

ADINA Thymosin Beta-4 product vial

Thymosin Beta-4

£62.00

Thymosin Beta-4 is endogenous 43-amino-acid actin-sequestering peptide. Researchers examine it in relation to cell migration, corneal repair, inflammation and tissue-remodelling biology.

Why it is distinct

Full-length endogenous thymosin beta-4 with broader actin biology, rather than the shorter TB-500-style material.

  • Evidence stageEarly human evidence
  • AvailabilityUnavailable
  • Batch recordPublished after verification
  • DispatchConfirmed at checkout

Out of stock

Ask about availability
SKU: ADINA-REC-THYMOSIN-BETA-4-10MG Category: Tags: , ,

PRODUCT INFORMATION

Clear first. Detailed when needed.

What this material is+

Thymosin Beta-4 is endogenous 43-amino-acid actin-sequestering peptide. Researchers examine it in relation to cell migration, corneal repair, inflammation and tissue-remodelling biology.

Research focus+

Researchers study whether it can support wound repair, reduce damaging inflammation and help tissue remodel after injury. Human evidence is limited and depends on the exact formulation and research setting.

How the mechanism differs+

Binds G-actin and influences cytoskeletal organisation, motility and repair-associated signalling.

Evidence and limitations+

Preclinical literature plus limited human development, particularly ophthalmic studies; not interchangeable with TB-500 fragments.

Testing and batch documentation+

No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.

RESEARCH PROFILE

Understand the distinction.

Molecular role

Endogenous 43-amino-acid actin-sequestering peptide

Research focus

Researchers study whether it can support wound repair, reduce damaging inflammation and help tissue remodel after injury. Human evidence is limited and depends on the exact formulation and research setting.

How it works

Binds G-actin and influences cytoskeletal organisation, motility and repair-associated signalling.

Key differentiator

Full-length endogenous thymosin beta-4 with broader actin biology, rather than the shorter TB-500-style material.

Evidence context

Preclinical literature plus limited human development, particularly ophthalmic studies; not interchangeable with TB-500 fragments.

Educational research context only. This information is not dosage, administration or personal-use guidance.

CONTINUE EXPLORING

Related research perspectives.

Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.